Peter C. Everett, MD

Assistant Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Peter Everett is an Assistant Professor of Medicine at Chobanian and Avedisian School of Medicine (BUSM) and a medical oncologist in the Section of Hematology and Medical Oncology at Boston Medical Center (BMC). He received his undergraduate degree from Cornell University and his medical degree from Chobanian and Avedisian School of Medicine. Following that, he completed training in Internal Medicine and a fellowship in Hematology and Medical Oncology at Boston Medical Center, where he also served as the Chief Fellow. Dr. Everett specializes in head, neck and thoracic oncology.

Publications

  • Published 3/10/2025

    Radwan A, Jani CT, Al Omari O, Patel M, Burns L, Mackay Z, Li L, Mahdaviani K, Davidson A, Weinberg J, Everett PC, Suzuki K, Mak KS, Kulke MH, Tapan U. The impact of immune-related adverse events on survival outcomes in a racially diverse population, with a focus on non-Hispanic Black patients. Oncologist. 2025 Mar 10; 30(3). PMID: 39603266.

    Read at: PubMed

  • Published 6/8/2023

    Qureshi MM, Lin Y, Moeller AR, Yan SX, Dyer MA, Suzuki K, Everett P, Litle V, Truong MT, Mak KS. Change in stage after neoadjuvant chemoradiation is associated with survival in patients with esophageal cancer. J Surg Oncol. 2023 Oct; 128(5):781-789. PMID: 37288789.

    Read at: PubMed

  • Published 8/1/2022

    Lee MH, Qureshi MM, Suzuki K, Everett P, Tapan U, Mak KS. Small cell lung cancer in young patients: trends in sociodemographic factors, diagnosis, treatment, and survival. J Thorac Dis. 2022 Aug; 14(8):2880-2893. PMID: 36071763.

    Read at: PubMed

  • Published 10/19/2021

    Hanna GJ, O'Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 02 01; 28(3):468-478. PMID: 34667025.

    Read at: PubMed

  • Published 8/3/2021

    Freydman J, Henshaw L, Patel JV, Smith CE, Everett PC. Combination EGFR and RET Inhibition in Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC. Ann Pharmacother. 2022 04; 56(4):503-504. PMID: 34344199.

    Read at: PubMed

View All 17 Publications:   View Full Profile in BUMC

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research
    Boston University

Websites

Education

  • Boston University School of Medicine, MD
  • Cornell University, BS

View all profiles